Log in

Speech and language disorders in patients with high grade glioma and its influence on prognosis

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

One hundred and sixteen patients wiht high grade glioma were entered into a prospective phase two study and treated with accelerated radiotherapy from 1988 to 1993. In this cohort of patients we analysed speech deficit as a subdivision of global functional status in terms of incidence, category and prognosis for survival.

Forty three patients (37%) had a speech deficit at presentation. Eighty percent of these had a component of expressive dysphasia, associated with considerable degree of awareness and distress. The overall median survival was 9.5 months. On univariate analysis, median survival in patients with speech difficulties (6 months) was worse than patients with normal speech (10.5 months) (log rang p = 0.005). Multivariate analysis established independent significance from age, Karnofsky Performance Status (KPS), gender, histological grade, extent of surgery and seizures.

This paper highlights the importance of assessing individual categories of functional disability which in patients with high grade glioma include mobility, cognitive function and communication. Each of these factors may seriously affect an individual's activities of daily living, hence quality of life and separate analysis has a number of clinical implications. Firstly, with over a third of patients suffering speech difficulties, adequate speech therapy facilities should be freely available to score the degree of deficit, devise co** strategies and institute communication therapy. Secondly, an understanding of prognostic factors aids the critical analysis of phase two studies and the design and stratification of future prospective trials which should include an analysis of speech deficit. Thirdly, separating individual patients into good and bad prognostic groups can assist strategic management decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. MRC Brain Tumour Working Party: Prognostic factors for malignant glioma: Development of a prognostic index. J Neuro-Oncol 9: 47, 1990

    Google Scholar 

  2. EORTC Brain Tumour Group: Evaluation of CCNU, VM-26 plus CCNU and procarbazine in supratentorial brain gliomas. J Neurosurg 55: 27, 1981

    Google Scholar 

  3. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein A, Fischbach J, Chang CC, Rotman M, Asbell S, Krisch R, Nelson D: Recursive partioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. Journal of the Cancer Institute 85:9: 769–705, 1993

    Google Scholar 

  4. Walker MD, Green SB, Byar DP & 14 others: Randomised comparisons of radiotherapy and nitrosoureas in the treatment of malignant glioma after surgery. N Eng J Med 3032: 1323, 1980

    Google Scholar 

  5. Green SB, Byan DP, Walker MD & 14 others: Comparison of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer treat. Rep 67: 121, 1983

    PubMed  Google Scholar 

  6. Walker MD, Alexander E, Hunt WE & nine others: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic astrocytomas. J neurosurg 49: 333, 1978

    PubMed  Google Scholar 

  7. Bleehen NM, Stenning SP on behalf of the MRC Brain Tumour Working Party: Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 64: 769–774, 1991

    PubMed  Google Scholar 

  8. Deutsch M, Green SB, Strike TA: Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16: 1389–96, 1986

    Google Scholar 

  9. Nelson JS, Curran WJ, Scott CB, Horton J: Hyperfractionated radiation therapy and bis-chloroethyl nitrosourea in the treatment of malignant glioma: Possible advantage Observed at 72 Gy in 1.2 Gy BID fractions: Report of the RTOG prot. 8302. Int J Radiat Oncol Biol Phys 25: 193–207, 1993

    PubMed  Google Scholar 

  10. Karnofsky D, Burchenal J: The clinical evaluation of chemotherapeutic agents in cancer. In: Mcleod CM (ed) Evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press: 1949, 191–205

    Google Scholar 

  11. Clark A, Fallowfield L: Quality of life measurements in patients with Malignant disease: A review. J.R. Soc Med 79: 165–169, 1986

    PubMed  Google Scholar 

  12. Brada M, Thomas G, Elyan S, Hines F, Ashley S, Stenning S: Improving acceptability of high dose radiotherapy by reducing the duration of treatment: Accelerated radiotherapy in high grade glioma. Journal of Neuro-Oncology Vol 21, No. 1, p. 20, 1994

    Google Scholar 

  13. Kernohan J, Sayre G: Tumours of the central nervous system-Astrocytomas. In: Firminger HT (ed) Atlas of Tumour Pathology, Section 10. Fascicle 35. Washington DC: Armed Forces Institute of Pathology, pp 313–332, 1952

    Google Scholar 

  14. Peto R, Pike MC, Armitage P, Breslow NEet al.: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Part 2. Analysi and examples. Br J Cancer Vol 35, No. 1, p 1–39, 1977

    PubMed  Google Scholar 

  15. Cox DR: Multivariate analysis of survival data: Regression models and life tables. J.R. Stat Soc B34, P187–220, 1972

    Google Scholar 

  16. Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett J: Stroke rehabilitation: analysis of repeated Bartel index measures. Arch Phys Med Rehabil 60: 14–17, 1979

    PubMed  Google Scholar 

  17. Gresham G, Philips T, Labi M: ADL status in stroke, relative merits of three standard indexes. Arch Phy Med Rehabil 61: 355–58, 1980

    Google Scholar 

  18. Haas J, Vogt G, Shiemann M, Patzold U: Aphasia and nonverbal inelligence in brain tumour patients. J Neurol 227: 209–218, 1982

    PubMed  Google Scholar 

  19. Kanzer M: Early symptoms of aphasia with brain tumours. J Nerv Ment Dis 95: 702–720, 1942

    Google Scholar 

  20. Miceli G, Caltagirone C, Gainotti G: Influence of age, sex, litaracy and pathological lesion on incidence, severity and type of aphasia. Acta Neurol Scand 64: 370–382, 1981

    PubMed  Google Scholar 

  21. Recht LD, Mckathy K, O'Donnell BF: Tumour-associated aphasia in left hemisphere brain tumours: The importance of age and tumour grade. Neurology 38: 48–50, 1989

    Google Scholar 

  22. Goodglass H, Kaplan E: Boston diagnostic examination booklet. Lea and Febiger 1983

  23. Mahoney F, Barthel D: Functional evaluation: the Barthel index. Marylands State Med J 14: 61–65, 1965

    Google Scholar 

  24. Chang CH, Horton J, Schonfield D & 6 others: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997, 1983

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, R., O'Connor, A.M. & Ashley, S. Speech and language disorders in patients with high grade glioma and its influence on prognosis. J Neuro-Oncol 23, 265–270 (1995). https://doi.org/10.1007/BF01059960

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059960

Key words

Navigation